Zolpidem tartarat je nebenzodijazepinski sedativ i hipnotik, koji se koristi za kratkotrajnu terapiju nesanice. Njegovi efekti se manifestuju vezivanjem za benzodiazepinsko vezujuće mesto na GABAA receptoru u CNS-u. Zolpidem baza, koji farmaceutski aktivan deo molekula, podleže laganoj hidrolizi u kiselim i baznim rastvorima usled nestabilnosti tercijarne amidne funkcionalne grupe prisutne u njegovoj strukturi. Proizvodi ove hidrolize su zolpacid i dimetilamin. Oksozolpidem, zolpiridin i zolpaldehid su takoñe potencijalni degradacioni proizvodi zolpidem-tartarata. Kako prisustvo degradacionih proizvoda može da utiče na hemijske, farmaceutske i toksikološke osobine doziranog oblika, prema ICH smernicama moraju da se ispituju sve nečistoće prisutne u doziranom obliku u količini većoj od 0.1%. Zbog toga je razvijena nova, brza RP-HPLC metoda za odreñivanje zolpidem-tartarata i ključnih degradacionih proizvoda. Kako na hromatografsko ponašanje analiziranih supstanci mogu da utiču različiti Zolpidem tartrate is a non-benzodiazepine sedative-hypnotic agent, used in the short-term management of insomnia. Its effects are expressed by binding to the benzodiazepine-binding site of the GABAA receptor in the CNS. Zolpidem base, which is pharmacological active part of the molecule, undergoes slow degradation in acidic solutions, due to instability of the tercial amide moiety present in the zolpidem structure. Products of that acid hydrolysis are zolpacid and dimethylamine. Oxozolpidem, zolpyridine and zolpaldehyde are also potential degradation products of zolpidem. The presence of degradation products could affect chemical, pharmaceutical and toxicological properties of the pharmaceutical dosage form. Therefore, determination of degradation products present in pharmaceutical dosage forms above 0.1 % level is necessary, according to ICH guidelines. A new, rapid RP-HPLC method for determination of zolpidem tartrate and degradation products was developed. Since the chromatographic behaviour